Skip to main content

Headache clinical trials at UCSD

5 in progress, 4 open to eligible people

Showing trials for
  • PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM

    open to eligible people ages 22 years and up

    Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.

    La Jolla 5363943, California 5332921 and other locations

  • Combined Transcranial Magnetic Stimulation and Therapy for MTBI Related Headaches

    open to eligible people ages 18-65

    This study will assess the combined effectiveness of repetitive transcranial magnetic stimulation (rTMS) and telehealth based therapy in helping manage mild traumatic brain injury (mTBI) related headaches. The investigators hypothesize that active rTMS combined with telehealth therapy will provide marked reduction in mTBI related headaches and symptoms in comparison to their placebo counterparts.

    San Diego 5391811, California 5332921

  • Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    open to eligible people ages 6-17

    The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).

    La Jolla 5363943, California 5332921 and other locations

  • Children and Adolescents With Migraine: Acute Treatment

    open to eligible people ages 6-17

    The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.

    La Jolla 5363943, California 5332921 and other locations

  • Inhaled Cannabis for Acute Migraine Treatment

    Sorry, currently not accepting new patients, but might later

    This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.

    La Jolla 5363943, California 5332921

Our lead scientists for Headache research studies include .

Last updated: